Evidence map›Paper›PMID 40638571›Full record

ArticlePLoS biology2025

H3K4me2 distinguishes a distinct class of enhancers during the maternal-to-zygotic transition.

Matthew D Hurton, Jennifer M Miller, Miler T Lee

Abstract read
In one paragraph

Article in PLoS biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Matthew D HurtonDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Jennifer M MillerDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
Miler T LeeDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.ORCID 0000-0003-0933-0551

Funding

Transcriptome reprogramming in the early embryoR35GM137973 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Miler T. S. Lee · 2020 to 2026
$2.3M
NIGMS NIH HHS R35 GM137973
6 · The paper itself

Abstract

After egg fertilization, an initially silent embryonic genome is transcriptionally activated during the maternal-to-zygotic transition. In zebrafish, maternal vertebrate pluripotency factors Nanog, Pou5f3 (OCT4 homolog), and Sox19b (SOX2 homolog) (NPS) play essential roles in orchestrating embryonic genome activation, acting as "pioneers" that open condensed chromatin and mediate acquisition of activating histone modifications. However, some embryonic gene transcription still occurs in the absence of these factors, suggesting the existence of other mechanisms regulating genome activation. To identify chromatin signatures of these unknown pathways, we profiled the histone modification landscape of zebrafish embryos using CUT&RUN. Our regulatory map revealed two subclasses of enhancers distinguished by presence or absence of H3K4me2. Enhancers lacking H3K4me2 tend to require NPS factors for de novo activation, while enhancers bearing H3K4me2 are epigenetically bookmarked by DNA hypomethylation to recapitulate gamete activity in the embryo, independent of NPS pioneering. Thus, parallel enhancer activation pathways combine to induce transcriptional reprogramming to pluripotency in the early embryo.

Indexed as

Enhancer Elements, GeneticHistonesZebrafishZygoteAnimalsChromatinDNA MethylationEmbryonic DevelopmentEmbryo, NonmammalianEpigenesis, GeneticFemaleGene Expression Regulation, DevelopmentalLysineNanog Homeobox ProteinOctamer Transcription Factor-3SOXB1 Transcription FactorsChromatinH3K4me2HistonesLysineNanog Homeobox ProteinNanog protein, zebrafishOctamer Transcription Factor-3Pou5f3 protein, zebrafishSOXB1 Transcription FactorsZebrafish Proteins

Identifiers

PMID40638571
PMCPMC12244696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.